CompletedPhase 4

Paravertebral Block to Reduce the Incidence of New Onset Atrial Fibrillation After Cardiac Surgery

United States32 participantsStarted 2021-04-09

Plain-language summary

The purpose if this pilot study is to determine if a perioperative infusion of 0.2% ropivacaine via bilateral T3 paravertebral catheters can decrease the incidence of new onset atrial fibrillation following primary CABG and/or valve surgery and compare a number of secondary outcomes.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: \- Participants must be undergoing one of the following elective or urgent (but not emergent) surgeries: A) Primary Coronary Artery Bypass Graft (CABG) B) Primary Surgical Aortic Valve Replacement (sAVR) C) Primary Surgical Mitral Valve Replacement (sMVR) D) Combined CABG \& surgical valve replacement Exclusion Criteria: * History of atrial fibrillation or flutter * Infective endocarditis * Left ventricular ejection fraction (LVEF) \< 30% * Emergency surgery * Redo surgery * Contraindication to block placement including local anesthetic allergy, bleeding diathesis (physiologic or iatrogenic) * Body mass index \> 35kg/m2 * Pregnancy

What they're measuring

Incidence of New-Onset Atrial Fibrillation (NOAF)

Timeframe: 5 days

Trial details

NCT IDNCT04472299

SponsorUniversity of Minnesota

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-07-08

View on ClinicalTrials.gov More New Onset Atrial Fibrillation trials